Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood

• Published in: Cancer chemotherapy and pharmacology Vol. 82; no. 5; pp. 887 - 898
• Main Authors: Liu, Z., Martin, J., Orme, L., Seddon, B., Desai, J., Nicholls, W., Thomson, D., Porter, D., McCowage, G., Underhill, C., Cranswick, N., Michael, M., Zacharin, M., Herschtal, A., Sivasuthan, J., Thomas, D. M.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2018; Springer Nature B.V
• Subjects: Adolescent; Adolescents; Adult; Age Factors; Antibiotics, Antineoplastic - administration & dosage; Antibiotics, Antineoplastic - pharmacokinetics; Antibiotics, Antineoplastic - therapeutic use; Bone Neoplasms - drug therapy; Bone Neoplasms - metabolism; Cancer Research; Children; Doxorubicin; Doxorubicin - administration & dosage; Doxorubicin - analogs & derivatives; Doxorubicin - pharmacokinetics; Doxorubicin - therapeutic use; Ewing's sarcoma; Ewings sarcoma; Female; Females; Gender; Hodgkin Disease - drug therapy; Hodgkin Disease - metabolism; Hodgkin's lymphoma; Humans; Lymphoma; Medicine; Medicine & Public Health; Models, Biological; Neoplasms - drug therapy; Neoplasms - metabolism; Oncology; Original Article; Osteosarcoma; Patients; Pharmacokinetics; Pharmacology/Toxicology; Pregnancy; Prospective Studies; Sarcoma, Ewing - drug therapy; Sarcoma, Ewing - metabolism; Sex Characteristics; Sex differences; Young Adult; Adolescent and young adult; Pharmacokinetics modelling; Ewing sarcoma; Osteosarcoma; Hodgkin’s lymphoma; Gender; Doxorubicin; Doxorubicinol

Purpose For many cancers, adolescents and young adults (AYA) have worse outcomes than for children and adults. Many factors may contribute to the AYA survival gap, including differences in biology, therapeutic intent, and adherence to therapy. It has been observed that male AYAs have poorer outcomes...